Inactive Instrument

LAM IND Stock Other OTC

US51280R1041

Biotechnology & Medical Research

End-of-day quote Other OTC
- ^USD	-

23/12/21	Parallel Industries Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2021	CI
27/09/19	Easton Pharmaceuticals Inc. cancelled the acquisition of Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada.	CI

Parallel Industries Inc., formerly Easton Pharmaceuticals, Inc., is a development-stage company engaged in various pharmaceutical sectors and other industries. The Company has a transdermal delivery technology (Viorra Delivery Matrix or VDM), which is incorporated in a line of therapeutic over-the-counter (OTC) products. The Company owns topically-delivered drugs and therapeutic/cosmetic healthcare products focused on cancer and other health problems geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions. The Company's products are in various stages of commercialization. The Company's products include Nauseasol, which is a motion sickness gel; Skin Renou HA, which is an anti-aging wrinkle cream; Kenestrin Gel, which is a pain relief gel; Viorra, which serves as an aid to the relief of female sexual arousal disorder (FSAD); XILIVE, which is an early-stage cancer drug, and FSAD) drug, which includes a water-based complex polymer matrix.

Employees

Sector

Biotechnology & Medical Research

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	269K 232K 218K 198K 373K 25.72M 378K 2.55M 1M 12.88M 1.01M 988K 42.86M	P/E 2019	-4.17x	P/E 2020	-4.29x
Enterprise Value	2.75M 2.38M 2.23M 2.03M 3.82M 263M 3.87M 26.12M 10.24M 132M 10.33M 10.11M 438M	EV / Sales 2019	6.27x	EV / Sales 2020	-
Free-Float	97.34%	Yield 2019 *	-	Yield 2020	-

23/12/21	Parallel Industries Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2021	CI
27/09/19	Easton Pharmaceuticals Inc. cancelled the acquisition of Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada.	CI
13/06/19	Easton Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	CI
30/04/19	Easton Pharmaceuticals Inc. Moves its Corporate Head Office	CI
26/04/19	Easton Pharmaceuticals Inc. acquired Supreme Sweets Inc. from Barbara and Mario Parravano.	CI
27/03/19	Easton Pharmaceuticals Inc. Signs LOI with Licensed Producer of Cannabis to Expand its Operations and Participate in its Cannabis Edibles Division	CI
11/03/19	Easton Pharmaceuticals Inc. Commences Cannabis Edibles Division	CI
05/02/19	Easton Pharmaceuticals Inc. Announces Updates on its $2,600,000 Framing Contract to Construct 150 Homes as Well as Other Initiatives	CI
23/01/19	Easton Pharmaceuticals Inc. Announces Sales Results for the Quarter Ended September 30, 2018 and December 31, 2018	CI
11/01/19	Easton Pharmaceuticals Inc. Provides Operational Update on CAD 2,600,000 Framing Contract	CI
02/01/19	Easton Pharmaceuticals Announces Signing and Commencement of CAD 2,600,000 Framing Contract to Construct 150 Homes	CI
29/11/18	Gunpowder Capital Corp. cancelled the acquisition of iBliss Inc. from Easton Pharmaceuticals Inc..	CI
27/09/18	Easton Pharmaceuticals Inc. signed a letter of intent to acquire Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada.	CI

29/12/21	EASTON PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q/A)	AQ
29/12/21	EASTON PHARMACEUTICALS INC. - 10-K/A - Management's Discussion and Analysis of Financial Condition and Results of Operations.	AQ
23/12/21	EASTON PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
23/12/21	EASTON PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
23/12/21	EASTON PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ

Manager	Title	Age	Since
Evan Karras CEO	Chief Executive Officer	-	30/06/2015
Vince Demasi COO	Chief Operating Officer	-	20/06/2018
Jose Tiran Saucedo CTO	Chief Tech/Sci/R&D Officer	-	01/01/2015

Director	Title	Age	Since
Evan Karras BRD	Director/Board Member	-	30/06/2015
Vince Demasi BRD	Director/Board Member	-	20/06/2018

LAM IND Stock Other OTC

Stocks

US51280R1041

Biotechnology & Medical Research

Valuation: LAM IND

Latest news : LAM IND

Press Releases: LAM IND

Managers and Directors: LAM IND

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.80%	+3.44%	+70.64%	+109.32%	73.25B
ARGENX SE	-0.65%	+13.40%	+48.13%	+89.30%	61.95B
INSMED INCORPORATED	+3.70%	-4.77%	+0.41%	+484.07%	28.02B
WUXI BIOLOGICS (CAYMAN) INC.	+5.24%	+5.65%	+56.71%	+21.30%	24.15B
BIONTECH SE	-1.60%	-1.29%	-19.31%	-19.10%	23.01B
PHARMAESSENTIA CORPORATION	-6.00%	+6.02%	+244.39%	+430.80%	18.35B
GENMAB A/S	+0.67%	+6.17%	+40.36%	-13.81%	19.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.83%	+2.65%	+21.42%	+557.58%	15.92B
EXELIXIS, INC.	+2.11%	-1.21%	+36.57%	+149.14%	12.96B
Average	+1.34%	+1.06%	+55.48%	+200.96%	30.79B
Weighted average by Cap.	+1.78%	+3.14%	+54.78%	+164.67%

	2019	2020
Net sales	1.56M 1.34M 1.26M 1.15M 2.16M 149M 2.19M 14.77M 5.79M 74.51M 5.84M 5.71M 248M	-
Net income	-323K -279K -262K -238K -448K -30.9M -454K -3.07M -1.2M -15.48M -1.21M -1.19M -51.5M	-189K -163K -153K -139K -262K -18.03M -265K -1.79M -701K -9.03M -708K -693K -30.04M
Net Debt	8.41M 7.26M 6.81M 6.2M 11.67M 804M 11.83M 79.86M 31.29M 403M 31.58M 30.9M 1.34B	2.48M 2.14M 2.01M 1.83M 3.44M 237M 3.49M 23.57M 9.24M 119M 9.32M 9.12M 396M